You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Selective kinase inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neurofibromatosis 1, Neurofibroma Plexiform Trial in Shanghai (Selumetinib)

Active, not recruiting
  • Neurofibromatosis 1
  • Neurofibroma Plexiform
  • Shanghai, China
  • +1 more
Jan 13, 2023

Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer Trial in Miami (AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor +

Not yet recruiting
  • Breast Cancer
  • +3 more
  • Miami, Florida
    University of Miami
Apr 12, 2023

Metastatic Breast Cancer Trial in East Melbourne (BYl719)

Completed
  • Metastatic Breast Cancer
  • East Melbourne, Victoria, Australia
    Peter MacCallum Cancer Centre
Aug 11, 2022

Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer Trial (Q702, Pembrolizumab)

Not yet recruiting
  • Esophageal Cancer
  • +3 more
  • (no location specified)
Jun 27, 2022

Adult Solid Tumor, Advanced Solid Tumor, Refractory Tumor Trial in Bruxelles, Edegem, Rotterdam (DO-2)

Recruiting
  • Adult Solid Tumor
  • +2 more
  • Bruxelles, Belgium
  • +2 more
Mar 1, 2023

Achondroplasia Trial in Australia, Spain, United Kingdom (Infigratinib)

Recruiting
  • Achondroplasia
  • Parkville, Victoria, Australia
  • +3 more
Apr 5, 2022

Neurofibromatosis Type 1 Trial in Japan (Selumetinib)

Active, not recruiting
  • Neurofibromatosis Type 1
  • Minato-ku, Japan
  • +3 more
Jun 9, 2022

Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in Columbus, Salt

Active, not recruiting
  • Prolymphocytic Leukemia
  • +4 more
  • Columbus, Ohio
  • +1 more
Apr 29, 2022

Part1: Advanced B-cell Malignancies, Part2: r/rCLL and r/rMCL, Part3: Untreated CLL Trial in Japan (Acalabrutinib, Obinutuzumab)

Active, not recruiting
  • Part1: Advanced B-cell Malignancies
  • +2 more
  • Chiba-shi, Japan
  • +13 more
Jan 31, 2022

Lung Tumor, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-701, osimertinib, carboplatin)

Recruiting
  • Lung Neoplasm
  • +26 more
  • Boston, Massachusetts
  • +6 more
Jun 23, 2022

Solid Tumor, Advanced Cancer, Metastatic Cancer Trial in Los Angeles, Chicago, Morristown (Q702)

Recruiting
  • Solid Tumor
  • +2 more
  • Los Angeles, California
  • +3 more
Jul 29, 2021

Advanced Solid Tumor, Metastatic Solid Tumor Trial (PEP07)

Not yet recruiting
  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • (no location specified)
Aug 1, 2023

Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in United States (NVL-655)

Recruiting
  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Orange, California
  • +13 more
Jan 31, 2023

SCLC, Small Cell Cancer, Advanced Solid Tumor Trial run by the NCI (Lurbinectedin, Berzosertib)

Recruiting
  • SCLC
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Infigratinib, Tamoxifen, Omnipaque 350)

Recruiting
  • Breast Cancer
  • +3 more
  • Stanford, California
    Stanford University
Feb 16, 2022

Acute Myeloid Leukemia, Lymphoma, Mantle-Cell Trial (PEP07)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Lymphoma, Mantle-Cell
  • (no location specified)
Dec 22, 2022

Achondroplasia Trial in Worldwide (Infigratinib 0.016 mg/kg, Infigratinib 0.032 mg/kg, Infigratinib 0.064 mg/kg)

Recruiting
  • Achondroplasia
  • Infigratinib 0.016 mg/kg
  • +3 more
  • Oakland, California
  • +17 more
Apr 5, 2022

Pancreatic Ductal Adenocarcinoma Trial (combination therapy with no MEKi, combination therapy with MEKi-HCQ, combination therapy

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • combination therapy with no MEKi
  • +3 more
  • (no location specified)
Nov 29, 2022

Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase

Recruiting
  • Liver Transplant
  • PVHA or TACE
  • Shanghai, Shanghai, China
    The value of tumor feeding vessels deprivation combined with tyr
Nov 26, 2022

Cushing Disease Trial (Fimepinostat)

Not yet recruiting
  • Cushing Disease
  • (no location specified)
Jul 31, 2023

NSCLC ALK-positive, NSCLC c-Met Dependent, NSCLC ROS Marker Positive Trial in Worldwide (PF-02341066, Rifampin, Itraconazole)

Completed
Has Results
  • Non-Small Cell Lung Cancer ALK-positive
  • +4 more
  • Orange, California
  • +28 more
Feb 15, 2022

Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated Hematologic Tumor

Active, not recruiting
  • Advanced Systemic Mastocytosis
  • +3 more
  • Stanford, California
  • +31 more
Mar 25, 2022

Liver Tumors Trial in Beijing (Tislelizumab plus tyrosine kinase inhibitor)

Recruiting
  • Liver Neoplasms
  • Tislelizumab plus tyrosine kinase inhibitor
  • Beijing, Beijing, China
    302 Hospital
Sep 22, 2023

Cyclin-dependent Kinase Inhibitor 2A on Labor-related Signals

Not yet recruiting
  • Preterm Labor
    • (no location specified)
    May 9, 2023

    Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

    Not yet recruiting
    • Lung Cancer
    • Non Small Cell Lung Cancer
    • Amivantamab 1050mg
    • +2 more
    • Aurora, Colorado
    • +2 more
    Apr 25, 2023